The first time I really paid attention to a screening guideline was the afternoon my father's primary care doctor stopped recommending cancer screening for him. He was eighty-two, in assisted living, on six medications, and the doctor pulled up a chair and said, in plain language, that any cancer they found at this point would probably be worse to treat than to leave alone. I had walked in expecting a chart of upcoming colonoscopies and PSA draws. I walked out with something more honest. Sometimes the best preventive medicine is the one you stop doing.
That conversation reshaped how I read screening recommendations. I had grown up assuming more tests meant more safety. It turns out the science is much more interesting than that. The U.S. Preventive Services Task Force, the American Cancer Society, the American College of Cardiology, and the American Diabetes Association have spent the last decade narrowing, expanding, and in some cases reversing their advice, and the 2026 picture for adults over sixty is sharper, and stranger, than most people realize. Here is what I have found worth knowing.
Heart and Vessels: The Tests That Earn Their Place
Cardiovascular screening is where the evidence is strongest and the routine has been settled the longest, so this is the easy part. Blood pressure gets checked at every visit, minimum once a year, and the 2017 ACC/AHA thresholds of 130/80 are still the U.S. baseline. What is newer is the conversation about how tight to push that number in older adults. European guidelines updated in 2024 walked back aggressive targets for patients seventy-five and up, citing the real risk of orthostatic hypotension, the dizzy stand-up that becomes a broken hip. The takeaway, at least from where I sit, is that blood pressure control matters but the number is not sacred. Home monitoring with a validated arm cuff (not a wrist gadget) gives a much truer picture than the office reading, which is almost always elevated by the drive over.
A lipid panel every five years is fine if you are low risk and not on a statin. If you are on a statin, or borderline, annual is more useful. The number that actually predicts events is not total cholesterol but LDL combined with your ten-year ASCVD risk score, which any clinic can pull up in a browser. Ask for the score, not just the lab printout. A low LDL with high ASCVD risk still merits a statin conversation; a borderline LDL with very low risk does not. The number means nothing without the context.
While we are in the cardiovascular section, a note on the apolipoprotein B test. ApoB is a more direct count of the atherogenic particles in your blood than the standard LDL number, and lipidologists increasingly prefer it. It is cheap, covered by most insurers when ordered, and worth asking about if your standard panel keeps coming back ambiguous or your family history is heavy. The American College of Cardiology has not made it a routine recommendation, but they no longer discourage it either. Granted, for most people the standard panel plus the risk calculator is plenty.
Two tests worth knowing about. The first is the AAA screening, an abdominal aortic aneurysm ultrasound, a one-time scan recommended by USPSTF for men sixty-five to seventy-five who ever smoked. It is non-invasive, takes fifteen minutes, and catches a condition that otherwise announces itself by rupturing. Women are generally not recommended for it. The second is the resting EKG in asymptomatic adults, which USPSTF rates a "D," meaning they recommend against it. If you have no symptoms, a routine EKG mostly produces false positives that lead to stress tests and catheterizations you did not need. Granted, if your doctor wants a baseline once, that is reasonable. Annual screening EKGs are not.
Cancer Screening: Where the Real Nuance Lives
This is the section where the guidelines have changed the most and where the conversation with your doctor matters the most. I am going to go test by test.
Colorectal. Colonoscopy every ten years remains the gold standard, and USPSTF recommends screening through age seventy-five. Between seventy-six and eighty-five it becomes individualized. Your overall health and life expectancy drive the decision. After eighty-five, the recommendation is to stop. For people who do not want a colonoscopy, FIT (annual stool test) and Cologuard (every three years) are both legitimate options. Worth knowing: Cologuard catches about ninety-two percent of actual cancers but only around forty percent of advanced adenomas (the precancerous polyps a colonoscopy would remove on the spot). That's the gap. If you have a family history or any prior polyps, the colonoscopy is the cleaner answer.
Breast. The 2024 USPSTF update lowered the starting age for mammography to forty and recommends biennial screening for women through seventy-four. For seventy-five and up, the task force says evidence is insufficient, meaning the decision belongs to the individual, weighted by overall health and how many more years you reasonably expect. The American Cancer Society still leans toward continuing annual screening as long as life expectancy is over ten years. Both positions are defensible. I would not let anyone bully you into either.
Cervical. This is the easiest one. If you are sixty-five or older, have had adequate prior screening, and no history of high-grade dysplasia, you can stop. If those conditions are not met, you keep going. The number of women still getting routine pap smears in their late seventies because no one ever told them to stop is a quiet problem.
Prostate. PSA is the screening test that has done the most harm of any I cover here, and the guidelines reflect that. USPSTF rates it a "C" for men fifty-five to sixty-nine, meaning shared decision-making, not automatic. For men seventy and over they rate it a "D," which means recommends against. A friend of my father's got a borderline PSA, then a biopsy with complications, then a Gleason 6 diagnosis (which today is increasingly classified as not even cancer), then a prostatectomy he did not need. That is the modal PSA story for an older man. If your doctor wants to draw it routinely past seventy without a conversation about what you would actually do with the result, push back.
Lung. This one expanded in 2021 and is genuinely underused. Low-dose CT, annually, for adults fifty to eighty with a twenty pack-year smoking history who currently smoke or quit within the last fifteen years. If you ever smoked seriously, ask about it. You stop screening fifteen years after quitting or when other health problems shorten the runway.
Skin. USPSTF gives this an "I," which means insufficient evidence for general screening, but for fair-skinned adults with sun history or a family history of melanoma, an annual dermatology check is a reasonable individual call. Self-exam using the ABCDE shorthand (asymmetry, border, color, diameter, evolution) is free and worth doing.
The ones not on the list. Pancreatic, ovarian, and testicular cancer screening is not recommended for average-risk adults. The Galleri multi-cancer blood test is interesting and may turn into something real, but the FDA has not approved it as a screening tool and the evidence base is still preliminary. I would not be paying out of pocket for it in 2026.
Bone, Sugar, and Thyroid
A DEXA scan, which measures bone density, has a baseline at sixty-five for women, seventy for men, earlier with risk factors. If the result is normal, every two years is plenty, and frequency tapers as you stay normal. If osteopenia or osteoporosis turns up, the FRAX score (a ten-year fracture probability calculator) is what your doctor will use to decide whether medication makes sense. Bisphosphonates and the newer agents are not free of side effects; the FRAX gives the conversation a real anchor.
Diabetes screening expanded in 2021 and now covers adults thirty-five to seventy with overweight or obesity, by A1C every three years. If you are pre-diabetic (A1C between 5.7 and 6.4), that moves to annual. A1C is more useful than fasting glucose because it reflects the last two to three months, not the breakfast you skipped.
Thyroid function (a TSH draw) is not on the USPSTF list as a routine screen for asymptomatic adults, but in practice most primary care doctors check it every few years past sixty because hypothyroidism is common and the symptoms (fatigue, weight gain, cold intolerance) get blamed on aging. I would not argue with a periodic TSH.
Vitamin D testing is in a similar category. USPSTF gives it an "I" for general population screening, but if you live north of about the fortieth parallel and spend most of your day indoors (which describes most of us), a single 25-hydroxyvitamin D level once is informative. The optimal range debate continues; thirty to fifty ng/mL is the working target most clinicians use. Routine annual testing in a stable patient is overkill. One baseline, then re-test if you supplement aggressively or your situation changes.
A final note on basic labs: a complete blood count and a basic metabolic panel get drawn at most annual visits and they earn their keep. The CBC catches anemia, which is common and undertreated in older adults; the BMP tracks kidney function, which matters enormously because so many medications are dosed by it. These are not glamorous tests. They are the ones that quietly catch the most actionable things.
Hearing, Vision, and the Senses That Quietly Go
USPSTF rates routine hearing screening for older adults an "I," insufficient evidence, but the American Academy of Audiology recommends a baseline test at sixty and every three years after, annually past seventy. I think the audiology folks have the better read here. Untreated hearing loss is associated with cognitive decline, social isolation, and falls. The test is fast, the over-the-counter hearing aid market has opened up considerably since the FDA rule change in 2022, and there is no good reason to wait until you cannot follow conversation at dinner. We covered the OTC hearing aid landscape in a separate piece.
Vision is more routine. Annual eye exam at sixty-five and up, dilated, with tonometry to screen for glaucoma. Glaucoma is the disease where catching it early actually changes the outcome. By the time you notice peripheral vision loss, you have already lost optic nerve fibers that do not grow back. Macular degeneration, cataracts, and diabetic retinopathy all get caught at the same visit. This is one of the highest-yield annual appointments you can keep.
Cognitive and Mental Health: The Harder Conversations
Medicare's Annual Wellness Visit includes a mandatory cognitive assessment. In practice, execution is variable. Sometimes it is a real Mini-Cog (three-item recall plus a clock draw), sometimes it is a single "do you feel forgetful?" question. If you want a real baseline, ask for the MoCA, which is more sensitive to mild cognitive impairment. I would offer one caution. The current treatments for MCI and early Alzheimer's are modest at best, and the new amyloid antibodies (lecanemab, donanemab) come with brain-bleed risks that have made even neurologists cautious. Aggressive early screening in a patient who does not want it can do real harm: to mood, to insurance, to autonomy. Push when it makes sense, do not push when it does not. Brain health overall is bigger than one test.
Depression screening with the PHQ-2 or PHQ-9 should be part of every annual physical. It usually is not, because the visit runs short. Ask for it. Late-life depression is treatable and badly under-diagnosed, and the Geriatric Depression Scale exists for a reason. Anxiety screening (USPSTF added the recommendation in 2023) is suggested for adults under sixty-five and rated "I" for older adults. The age cutoff there is more about evidence gaps than about whether older adults experience anxiety. We do. Get screened anyway.
A related point worth flagging: the Medicare Annual Wellness Visit is not a full physical exam, despite the name. It is a checklist-driven preventive planning visit, covered at no cost, and it produces a personalized prevention plan. The actual physical, the laying-on-of-hands part where the doctor listens to your heart and lungs and looks in your ears, is a separate visit billed differently. A lot of people leave the Annual Wellness Visit thinking they got their yearly physical and they did not. Schedule both, or be clear about which one you are getting.
Vaccines, Which Are Screening-Adjacent
These get forgotten in screening articles, but they belong in the same conversation because they are the other half of preventive medicine. The 2026 picture for adults sixty and over: Shingrix, two doses, anyone fifty and up; pneumococcal, either a single PCV20 or the older PCV15 followed by PPSV23, for everyone sixty-five and up; high-dose or adjuvanted flu vaccine annually; the updated COVID vaccine annually; and the RSV vaccine, which the FDA approved in 2023 for adults sixty and older under shared clinical decision-making. The RSV vaccine is the one most often missed. RSV puts a lot of older adults in the hospital every winter, and the vaccine is genuinely good. One more reason to keep Shingrix on the list: the shingles vaccine appears to protect the heart, too, with recent research linking it to a lower risk of cardiovascular events.
What I Would Skip, and What I Would Stop
A few things I would not spend money or worry on. The direct-to-consumer wellness panels, Function Health and the like, sell two hundred biomarkers for a few hundred dollars and generate mostly noise. Most of those markers do not have established clinical action thresholds in healthy adults, and the panels are designed to surface borderline numbers that drive engagement with the platform. If you want a real read on your cardiovascular and metabolic health, your primary care doctor can order the same labs through insurance.
Full-body MRIs sold by Prenuvo and similar services have the same problem at a larger scale. They are very good at finding incidentalomas (anatomical findings that mean nothing but cannot be left unexplained), and they lead to follow-up workups that have their own complication rates. The radiology societies have been clear: outside specific high-risk situations, these are not recommended.
And the bigger point, the one my father's doctor made to me that afternoon. Stopping screening is a legitimate, often correct medical decision. If your life expectancy is under ten years because of other conditions, most cancer screening stops paying off. The five-year survival benefit of catching a slow-growing cancer at age eighty-five is mathematically thin, and the harms of biopsy and treatment in a frail patient are not. I am not the master of this calculus yet (nobody is, exactly), but the willingness to stop is part of taking screening seriously, not the opposite of it.
Which gets me back to the doctor's office. Bring your medication list, bring your family history, bring your real questions, and ask which screens still earn their place this year. The right answer is going to look different at sixty-five, seventy-five, and eighty-five. And the right answer might, eventually, be fewer tests, not more. That is not a failure of medicine. It is medicine doing its job.
